收费全文 | 251277篇 |
免费 | 18373篇 |
国内免费 | 1126篇 |
耳鼻咽喉 | 2787篇 |
儿科学 | 6494篇 |
妇产科学 | 4595篇 |
基础医学 | 33028篇 |
口腔科学 | 4555篇 |
临床医学 | 25324篇 |
内科学 | 53446篇 |
皮肤病学 | 3384篇 |
神经病学 | 24246篇 |
特种医学 | 8401篇 |
外国民族医学 | 11篇 |
外科学 | 38459篇 |
综合类 | 3459篇 |
一般理论 | 318篇 |
预防医学 | 21353篇 |
眼科学 | 6549篇 |
药学 | 16973篇 |
5篇 | |
中国医学 | 362篇 |
肿瘤学 | 17027篇 |
2023年 | 1208篇 |
2022年 | 2046篇 |
2021年 | 5439篇 |
2020年 | 3263篇 |
2019年 | 5301篇 |
2018年 | 5956篇 |
2017年 | 4477篇 |
2016年 | 4959篇 |
2015年 | 5834篇 |
2014年 | 8607篇 |
2013年 | 11802篇 |
2012年 | 18028篇 |
2011年 | 18905篇 |
2010年 | 10588篇 |
2009年 | 9437篇 |
2008年 | 16606篇 |
2007年 | 17462篇 |
2006年 | 17312篇 |
2005年 | 17285篇 |
2004年 | 16197篇 |
2003年 | 15047篇 |
2002年 | 14075篇 |
2001年 | 2120篇 |
2000年 | 1602篇 |
1999年 | 2328篇 |
1998年 | 3071篇 |
1997年 | 2566篇 |
1996年 | 2183篇 |
1995年 | 2098篇 |
1994年 | 1744篇 |
1993年 | 1572篇 |
1992年 | 1262篇 |
1991年 | 1160篇 |
1990年 | 1008篇 |
1989年 | 980篇 |
1988年 | 976篇 |
1987年 | 954篇 |
1986年 | 958篇 |
1985年 | 967篇 |
1984年 | 1221篇 |
1983年 | 1127篇 |
1982年 | 1368篇 |
1981年 | 1315篇 |
1980年 | 1146篇 |
1979年 | 707篇 |
1978年 | 748篇 |
1977年 | 636篇 |
1976年 | 586篇 |
1975年 | 474篇 |
1974年 | 477篇 |
Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献